Imara

June 16, 2020

EHA 2020 – the sickle cell competition hots up

Behind Global Blood and Novartis, Bluebird leads a pack of biotechs wanting a slice of the sickle cell disease market.

April 09, 2020

Covid-19 stalls biotech flotations

Several young drug developers managed to float in the first quarter, but new issues dried up in March when coronavirus infected the markets. Is the game back on?

August 24, 2018

Global Blood makes second sickle cell bet

April 12, 2018

Global Blood aims for sickle cell dominance

Global Blood punching above its weight in sickle cell as 2022 sales forecasts for voxelotor hit $529m in 2022.

Imara

EHA 2020 – the sickle cell competition hots up

Covid-19 stalls biotech flotations

Global Blood makes second sickle cell bet

Global Blood aims for sickle cell dominance

Latest Reports

Evaluate Vantage Pharma, Biotech & Medtech Half-Year Review 2020

Evaluate Vantage COVID-19 Report

Editor's Picks

Esmo 2020 preview – late-breaking immunotherapy

Esmo 2020 preview – a kidney cancer showdown gets star billing

Big pharma spinouts grow up

Covid vaccine developers face nervous wait

Medtechs that book the most sales per employee face the greatest losses